



**CERTIFICATE OF SKIN SAFETY:
A MODIFIED DRAIZE REPEAT INSULT PATCH TEST IN A SHARED PANEL OF 109 HEALTHY VOLUNTEERS,
TO INVESTIGATE THE IRRITATION AND SENSITISATION POTENTIAL OF TEST ARTICLES FOLLOWING
REPEATED CUTANEOUS PATCH APPLICATIONS**

Conducted According to PCR Master Protocol: PCRRIP1 (9NOV2021)

PCR Study Number: **HLCRIP1M**

The study was conducted single blind, at a single center according to Master Protocol: PCRRIP1.

The test articles listed below were patched under occlusive conditions. A total of nine inductions patches worn by subjects for 47/71 hours (patching occurred Mondays, Wednesdays and Fridays) for approximately three weeks. Subjects had a rest period of 14 days. Challenge patches were applied to subjects for 48 hours and skin evaluations were made 1 hour and 48 hours post removal.

TEST ARTICLES - Example:

1. **Heliconia Face Toner**
2. **Heliconia Face and Body Scrub CAFÉ & MENTA**
3. **Heliconia Sensuous Body Oil**

Study Started: 7th April 2025 Study Completed: 9th MAY 2025

As demonstrated by the individual skin responses to the test articles (Refer to Summary Report for PCR Corp. Study Number: HLCRIP1M) the following can be concluded:

The test articles are considered as safe for use under the conditions of the study, and claims such as, "Dermatologically Tested", "Clinically Tested", "Clinically Proven", "Kind to Skin", "Safe for Skin", "Mild for Skin", "Hypoallergenic", "Allergy Tested", "Non-Irritating" and "Suitable for all Skin Types" are substantiated.

I declare that the PCR Corp. Summary Report HLCRIP1M constitutes a true and faithful account of the procedures adopted and the results obtained in the performance of this study. The aspects of the study conducted by Princeton Consumer Research Corp. were performed according to the Master Protocol, PCR Corp. SOPs and where relevant, in accordance with the Principles of Good Clinical Practice.

Signature of Principal Investigator:

A handwritten signature in black ink that reads 'B Drewitt'.

Barrie Drewitt
Title: Technical Director
PCR Corporation

10 / 06 / 2025

Date